Table V.
Clinical Investigation of Therapeutics for Reduced IVT Dosing Frequency
| Technology | Sponsor | Mechanism of action | Latest phase |
|---|---|---|---|
| Bioresorbable hydrogel containing tyrosine kinase inhibitor | Ocular Therapeutix | Tyrosine kinase inhibitor | Phase I |
| Anti-VEGF mAb conjugated to a phosphorylcholine-based biopolymer | Kodiak Sciences | Anti-VEGF | Phase III |
| Bispecific antibody angiopoietin-2/VEGF-A (Faricimab) | Roche | Anti-VEGF Anti-Ang-2 | Phase III |
| Sunitinib malate microparticle depot | Graybug Vision | Anti-VEGF | Phase IIa/Phase IIb |
| ADVM-022 IVT gene therapy | Adverum Biotechnologies | Anti-VEGF | Phase II |
| Fusion protein aflibercept—high dose | Regeneron Pharmaceuticals | Anti-VEGF | Phase II/III |
| Port delivery system | Roche | Anti-VEGF | Phase III |